In brief, this model allows us to create triple-negative mammary tumors, driven by WNT1, but optionally also containing a MYC-ERT2 construct, which expresses supraphysiological levels of the MYC-ER fusion protein and is activated by administration of tamoxifen. The gene discussed is MYC; the disease is breast cancer.